Takami Sato

Locoregional immuno(bio)therapy for liver metastases.

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.

Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy.

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.

A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.

The biology and management of uveal melanoma.

Locoregional treatment of malignant hepatic tumors with biologic response modifiers.

Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential.

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.

High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Locoregional management of hepatic metastasis from primary uveal melanoma.

Conjunctival melanoma: bladder and upper urinary tract metastases.

Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development.

Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.

Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study.

Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma.

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma.

Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes.

The potential role of sunitinib targeting melanomas.

Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.

High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.

Transhepatic therapies for metastatic uveal melanoma.

Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.

Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Tumor necrosis factor-α blockade and development of uveal melanoma: expected adverse effect or just coincidence?

Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

Successes and setbacks of early investigational drugs for melanoma.

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).

Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells.

Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes.

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.

Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma.

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.

CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.

Effects of Oncogenic Gα and Gα Inhibition by FR900359 in Uveal Melanoma.

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma.

A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.